Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
December’s full moon is the last supermoon of the year. Here’s what to know- Medicine doesn’t just have ‘conscientious objectors’ − there are ‘conscientious providers,’ too
- Criminal Guard Lawyer Expenses: What Would it be advisable for you to Hope to Pay?
- U.K. blocks Kanye West from entering Britain to headline now canceled festival: What led to the ban
- The 2026 'Super Bowl of Astronomy' starts today — here's what's happening
- Artemis 2 astronauts see Earth in the rear-view mirror | Space photo of the day for April 3, 2026
- How much would you pay to meet a Real Housewife? At BravoCon, the limit does not exist.
- Vote In favor of Your Favored Kind Of Cheddar
- Expert advice for new stargazers: How to begin your amateur astronomy journey
